494769-34-5

Basic information

• Product Name: (4-FORMYLTHIAZOL-2-YL)CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: TERT-BUTYL 4-FORMYLTHIAZOL-2-YLCARBAMATE;(4-FORMYLTHIAZOL-2-YL)CARBAMIC ACID TERT-BUTYL ESTER;(4-FORMYLTHIAZOL-2-YL)CARBAMIC ACID TERT-BUTYL ESTER, 95+%;N-Boc-2-amino-4-formylthiazole
• CAS NO: 494769-34-5
• Molecular Formula: C9H12N2O3S
• Molecular Weight: 228.27
• Mol File: 494769-34-5.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Density: 1.32 g/cm³
• Refractive Index: 1.603
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.89±0.70(Predicted)
• CAS DataBase Reference: (4-FORMYLTHIAZOL-2-YL)CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-FORMYLTHIAZOL-2-YL)CARBAMIC ACID TERT-BUTYL ESTER(494769-34-5)
• EPA Substance Registry System: (4-FORMYLTHIAZOL-2-YL)CARBAMIC ACID TERT-BUTYL ESTER(494769-34-5)

Safety Data

• Hazardous Substances Data: 494769-34-5(Hazardous Substances Data)

Usage

General Description

The chemical (4-Formylthiazol-2-yl)carbamic acid tert-butyl ester, also known as TFFCA, is a synthetic compound with the molecular formula C10H15N3O3S. It is a derivative of thiazole and is commonly used as a pharmaceutical intermediate in the synthesis of various pharmaceutical compounds. TFFCA has a wide range of applications, including as an intermediate in the preparation of potential antitumor agents and as a building block in the synthesis of various heterocycles. It is also utilized in the development of 5-HT1A receptor agonists and in the development of potential treatments for neurological disorders. TFFCA is known for its high purity and can be used in research and development as well as in the manufacturing of pharmaceuticals. Overall, TFFCA is a valuable chemical compound with diverse applications in pharmaceutical research and development.

InChI:InChI=1/C9H12N2O3S/c1-9(2,3)14-8(13)11-7-10-6(4-12)5-15-7/h4-5H,1-3H3,(H,10,11,13)

Upstream product

• 189512-01-4 ethyl 2-[(tert-butoxycarbonyl)amino]thiazole-4-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1100350-49-9 tert-butyl (4-((methoxy(methyl)amino)methyl)thiazol-2-yl)carbamate 
• 1108653-08-2 tert-butyl (5-fluoro-4-((methoxy(methyl)amino)methyl)thiazol-2-yl)carbamate 
• 850429-62-8 methyl 2-[[(tert-butoxy)carbonyl]amino]-1,3-thiazole-4-carboxylate 
• 494769-44-7 (4-hydroxymethylthiazol-2-yl)carbamic acid tert-butyl ester 

Downstream Products

• 98020-38-3 2-Amino-4-formyl-thiazol 
• 947179-19-3 (4-Difluoromethylthiazol-2-yl)-carbamic acid tert-butyl ester 

Relevant articles and documents

4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors

Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are constitutively overexpressed in many types of cancer cells and exert important immunosuppressive functions. In this article, a series of 4,6-substituted-1H-indazole derivatives were synthesized and evaluated the inhibitory activities against IDO1 and TDO, as well as their structure-activity relationships (SARs). Among these, compound 35 displayed the most IDO1 inhibitory potency with an IC50 value of 0.74 μM in an enzymatic assay and 1.37 μM in HeLa cells. Quantitative analysis of the Western blot results indicated that 35 significantly decreased the INFγ-induced IDO1 expression in a concentration-dependent manner. In addition, 35 showed promising TDO inhibition with an IC50 value of 2.93 μM in the enzymatic assay and 7.54 μM in A172 cells. Moreover, compound 35 exhibited in vivo antitumor activity in the CT26 xenograft model. These findings suggest that 1H-indazole derivative 35 is a potent IDO1/TDO dual inhibitor, and has the potential to be developed for IDO1/TDO-related cancer treatment.

Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4 and A are as described herein, compositions including the compounds and methods of using the compounds.

6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula:, wherein R1, R2, R3, R4 and A are as described herein, compositions including the compounds and methods of using the compounds.